VEGFA and hypertensive disorder: Furthermore, there are only a few reports about predictive and/or surrogate biomarkers of treatment efficacy for second‐line VEGF inhibitor containing chemotherapy12, 19 although there is several reports that hypertension may be surrogate marker of clinical outcome of first‐line chemotherapy with BEV in mCRC.20, 21